SCHEMBL3774153

SCHEMBL3774153

CC(=O)N1CCN(CC(=O)N2CCN(C3CCC3)CC2)CC1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.50
GAA P10253 2/20 0.49
ALDH1A1 P00352 4/20 0.48
KDM4E B2RXH2 3/20 0.48
SIGMAR1 Q99720 1/20 0.47
LMNA P02545 1/20 0.45
RECQL P46063 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
PARP1 P09874 1/20 0.44
HTT P42858 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
TSHR P16473 2/20 0.42
ALOX15 P16050 1/20 0.42
HSD17B10 Q99714 1/20 0.42
PKM P14618 1/20 0.42
PIK3CD O00329 1/20 0.41
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3773267 0.97 SIGMAR1 (0.50) HRH3GAAALDH1A1KDM4ESIGMAR1
SCHEMBL3765276 0.95 SIGMAR1 (0.52) HRH3GAAALDH1A1KDM4ESIGMAR1
SCHEMBL3767809 0.89 SIGMAR1 (0.57) HRH3GAAALDH1A1KDM4ESIGMAR1
SCHEMBL4550241 0.85 POLB (0.50) HRH3ALDH1A1KDM4EHSD17B10
SCHEMBL3767545 0.84 HSD11B1 (0.54) GAAALDH1A1KDM4ESIGMAR1LMNA
SCHEMBL3766167 0.84 SIGMAR1 (0.50) HRH3GAAALDH1A1KDM4ESIGMAR1
SCHEMBL3775828 0.84 KDM4E (0.65) HRH3GAAALDH1A1KDM4ESIGMAR1
SCHEMBL3773620 0.83 KDM4E (0.68) GAAALDH1A1KDM4ESIGMAR1LMNA
SCHEMBL13005640 0.83 KDM4E (0.68) GAAALDH1A1KDM4ESIGMAR1LMNA
SCHEMBL3769348 0.82 GAA (0.69) HRH3GAAALDH1A1KDM4ESIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 HRH3 2/4885GAA 2143/4885ALDH1A1 1210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.